Alembic Pharma jumps over 6% on getting approval from USFDA for Mesalamine extended-release capsules

“The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Apriso Extended-Release Capsules, 0.375 g, of Salix Pharmaceuticals, Inc. (Salix). Mesalamine Extended-Release Capsules are indicated for the maintenance of remission of ulcerative colitis in adults,” the company said in a BSE filing.